Accurate molar masses of cellulose for the determination of degradation rates in complex paper samples.

Complex cellulosic samples are often difficult to analyse with size-exclusion chromatography. The strong molecular associations of hemicelluloses and lignin with cellulose produce multimodal molar mass distributions (MMD) that are difficult to interpret. More reliable ways of calculating the molar masses of cellulose are thus necessary. This is particularly relevant when studying the kinetics of paper degradation, as the number average molar mass is the most precise indicator. In this study various data handling methods based on the deconvolution of bimodal and multimodal MMDs of complex cellulosic samples after SEC-MALS-DRI analysis are examined in order to propose more accurate paper degradation rates. Two deconvolution methods, which do or do not rely on polymer calibration curves were developed and were applied to several kraft and groundwood pulp papers unaged and hygrothermally aged. The deconvolution methods are discussed and evaluated in light of calculated cellulose activation energies, degradation rates and paper usable lifetime predictions.

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.

PURPOSE: Dendritic cells (DCs) are potent antigen-presenting cells that are uniquely capable of inducing tumor-specific immune responses. We have conducted a Phase I trial in which patients with metastatic breast and renal cancer were treated with a vaccine prepared by fusing autologous tumor and DCs. EXPERIMENTAL DESIGN: Accessible tumor tissue was disrupted into single cell suspensions. Autologous DCs were prepared from adherent peripheral blood mononuclear cells that were obtained by leukapheresis and cultured in granulocyte macrophage colony-stimulating factor, interleukin 4, and autologous plasma. Tumor cells and DCs were cocultured in the presence of polyethylene glycol to generate the fusions. Fusion cells were quantified by determining the percentage of cells that coexpress tumor and DC markers. Patients were vaccinated with fusion cells at 3-week intervals and assessed weekly for toxicity, and tumor response was assessed at 1, 3, and 6 months after completion of vaccination. RESULTS: The vaccine was generated for 32 patients. Twenty-three patients were vaccinated with 1 x 10(5) to 4 x 10(6) fusion cells. Fusion cells coexpressed tumor and DC antigens and stimulated allogeneic T-cell proliferation. There was no significant treatment-related toxicity and no clinical evidence of autoimmunity. In a subset of patients, vaccination resulted in an increased percentage of CD4 and CD8+ T cells expressing intracellular IFN-gamma in response to in vitro exposure to tumor lysate. Two patients with breast cancer exhibited disease regressions, including a near complete response of a large chest wall mass. Five patients with renal carcinoma and one patient with breast cancer had disease stabilization. CONCLUSIONS: Our findings demonstrate that fusion cell vaccination of patients with metastatic breast and renal cancer is a feasible, nontoxic approach associated with the induction of immunological and clinical antitumor responses.